An Endocannabinoid-Boosting Drug Reduced Tics in Tourette Syndrome
A single dose of a drug that boosts endocannabinoid levels significantly reduced tics and premonitory urges in Tourette syndrome patients in a Phase 1 crossover trial.
Quick Facts
What This Study Found
A single 40 mg dose of Lu AG06466 (a MAGL inhibitor that raises 2-AG endocannabinoid levels) showed an overall trend of tic reduction across all scales, with 2 of 3 tic scales (including the Yale Global Tic Severity Score) showing significant improvement versus placebo at various timepoints. Premonitory urges were also significantly reduced.
Key Numbers
20 patients; 40 mg single dose; 2/3 tic scales showed significant improvement; premonitory urges significantly reduced; common side effects: headache, somnolence, fatigue
How They Did This
Phase 1b double-blind crossover study in 20 adult Tourette syndrome patients on standard medications. Single fasted dose of Lu AG06466 (40 mg) or placebo in each period, with tic assessments at multiple timepoints.
Why This Research Matters
Tourette syndrome lacks consistently effective treatment. This is the first trial of a MAGL inhibitor (which works by boosting the body's own endocannabinoids rather than introducing external cannabinoids) in TS patients.
The Bigger Picture
Rather than using cannabis directly, this approach leverages the body's own endocannabinoid system by preventing breakdown of 2-AG. If confirmed in larger trials, it could provide tic relief without cannabis-related side effects.
What This Study Doesn't Tell Us
Only 20 patients. Single-dose study cannot assess long-term efficacy or safety. Phase 1b exploratory trial, not a definitive efficacy study.
Questions This Raises
- ?Would repeated dosing maintain or increase the tic-reducing effect?
- ?Could MAGL inhibitors work for other conditions where endocannabinoid deficiency is suspected?
Trust & Context
- Key Stat:
- Significant tic reduction from a single dose
- Evidence Grade:
- Small Phase 1b crossover trial providing proof-of-concept, but larger and longer trials are needed.
- Study Age:
- Published in 2022
- Original Title:
- Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study.
- Published In:
- Pharmacopsychiatry, 55(3), 148-156 (2022)
- Authors:
- Müller-Vahl, Kirsten R(12), Fremer, Carolin(7), Beals, Chan, Ivkovic, Jelena, Loft, Henrik, Schindler, Christoph
- Database ID:
- RTHC-04086
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can endocannabinoid drugs help Tourette syndrome?
This trial found a single dose of Lu AG06466, which boosts natural endocannabinoid levels by blocking their breakdown, significantly reduced tics on 2 of 3 scales and reduced premonitory urges in 20 adults with TS.
How is this different from using cannabis for tics?
Instead of introducing external cannabinoids (like THC), this drug boosts the body's own endocannabinoid 2-AG by inhibiting the enzyme that breaks it down. This approach may avoid cannabis-related side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04086APA
Müller-Vahl, Kirsten R; Fremer, Carolin; Beals, Chan; Ivkovic, Jelena; Loft, Henrik; Schindler, Christoph. (2022). Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study.. Pharmacopsychiatry, 55(3), 148-156. https://doi.org/10.1055/a-1675-3494
MLA
Müller-Vahl, Kirsten R, et al. "Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study.." Pharmacopsychiatry, 2022. https://doi.org/10.1055/a-1675-3494
RethinkTHC
RethinkTHC Research Database. "Endocannabinoid Modulation Using Monoacylglycerol Lipase Inh..." RTHC-04086. Retrieved from https://rethinkthc.com/research/muller-vahl-2022-endocannabinoid-modulation-using-monoacylglycerol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.